Jazz Pharmaceuticals Plc Stock Today

JAZZ Stock  USD 125.10  5.86  4.91%   

Performance

6 of 100

 
Weak
 
Strong
Modest

Odds Of Distress

Less than 1

 
High
 
Low
Very Small
Jazz Pharmaceuticals is trading at 125.10 as of the 21st of November 2024; that is 4.91 percent increase since the beginning of the trading day. The stock's open price was 119.24. Jazz Pharmaceuticals has a very small chance of experiencing financial distress in the next few years but had a somewhat modest performance during the last 90 days. Equity ratings for Jazz Pharmaceuticals PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of August 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
1st of June 2007
Category
Healthcare
Classification
Health Care
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland. The company has 60.45 M outstanding shares of which 3.59 M shares are currently shorted by private and institutional investors with about 7.01 trading days to cover. More on Jazz Pharmaceuticals PLC

Moving against Jazz Stock

  0.56VIRX Viracta TherapeuticsPairCorr
  0.54ME 23Andme HoldingPairCorr
  0.49DTIL Precision BioSciencesPairCorr
  0.47DRRX DurectPairCorr
  0.44VINC Vincerx PharmaPairCorr
  0.36VALN Valneva SE ADR Downward RallyPairCorr

Jazz Stock Highlights

ESG Sustainability
Environmental
Governance
Social
ChairmanBruce Cozadd
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Pharmaceutical, NASDAQ Composite, SP Midcap 400, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal Testing
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.520.3365
Way Up
Pretty Stable
Gross Profit Margin0.710.8864
Significantly Down
Pretty Stable
Total Current Liabilities1.6 B1.5 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total6.4 B6.1 B
Sufficiently Up
Slightly volatile
Total Assets12 B11.4 B
Sufficiently Up
Slightly volatile
Total Current Assets3.4 B3.3 B
Sufficiently Up
Slightly volatile
Debt Levels
Jazz Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Jazz Pharmaceuticals' financial leverage. It provides some insight into what part of Jazz Pharmaceuticals' total assets is financed by creditors.
Liquidity
Jazz Pharmaceuticals PLC currently holds 5.79 B in liabilities with Debt to Equity (D/E) ratio of 2.12, implying the company greatly relies on financing operations through barrowing. Jazz Pharmaceuticals PLC has a current ratio of 3.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Jazz Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Net Income

435.57 Million
Jazz Pharmaceuticals PLC (JAZZ) is traded on NASDAQ Exchange in USA. It is located in Waterloo Exchange, Dublin, Ireland, D04 E5W7 and employs 2,800 people. Jazz Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.21 B. Jazz Pharmaceuticals PLC conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 60.45 M outstanding shares of which 3.59 M shares are currently shorted by private and institutional investors with about 7.01 trading days to cover. Jazz Pharmaceuticals PLC currently holds about 899.36 M in cash with 1.09 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28.
Check Jazz Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Jazz Pharmaceuticals PLC has a total of 60.45 Million outstanding shares. The majority of Jazz Pharmaceuticals PLC outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Jazz Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Jazz Pharmaceuticals PLC. Please pay attention to any change in the institutional holdings of Jazz Pharmaceuticals PLC as this could imply that something significant has changed or is about to change at the company. Also note that almost one million thirty-nine thousand eight hundred nineteen invesors are currently shorting Jazz Pharmaceuticals expressing very little confidence in its future performance.
Check Jazz Ownership Details

Jazz Stock Institutional Holders

InstituionRecorded OnShares
Polaris Capital Management, Llc2024-09-30
1.3 M
Camber Capital Management Llc2024-09-30
1.1 M
Geode Capital Management, Llc2024-06-30
1.1 M
Franklin Resources Inc2024-06-30
1.1 M
Renaissance Technologies Corp2024-09-30
M
Ecor1 Capital, Llc2024-06-30
M
Swedbank Ab2024-09-30
M
Fmr Inc2024-09-30
835.9 K
Thompson, Siegel & Walmsley Llc2024-09-30
781.2 K
Blackrock Inc2024-06-30
6.1 M
Vanguard Group Inc2024-09-30
6.1 M
View Jazz Pharmaceuticals Diagnostics

Jazz Pharmaceuticals Historical Income Statement

At this time, Jazz Pharmaceuticals' Gross Profit is fairly stable compared to the past year. Research Development is likely to rise to about 892.1 M in 2024, despite the fact that Income Tax Expense is likely to grow to (113.9 M). View More Fundamentals

Jazz Stock Against Markets

Jazz Pharmaceuticals Corporate Management

Finbar LarkinVP OperationsProfile
George EliadesSenior OfficerProfile
Daniel SwisherNonExecutive EmployeeProfile
Patricia CarrSenior OfficerProfile
Jed MDSenior MedicineProfile
Andrea FlynnVP RelationsProfile

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.